Effect of IV magnesium supplementation in reducing adverse cisplatin associated kidney outcomes
Abstract
12123
Background:
Cisplatin is a commonly used chemotherapy agent that is associated with significant nephrotoxicity due to renal tubular cell injury. IV magnesium (mg) has emerged as a potential agent for preventing cisplatin-induced kidney injury. This study aims to explore the efficacy of IV mg in reducing cisplatin induced major adverse kidney events (MAKE).
Methods:
This is a retrospective observation cohort study of the TriNetX research network (with NLP) which included 105 Health care organizations (HCOs). Patients who received first dose of IV Cisplatin between 09/30/2004 to 09/30/2024 were included. Cohort further divided into two groups based on IV Mg supplementation during chemotherapy: IV Mg and Control groups. To mitigate potential confounding variables, we conducted 1:1 propensity score matching (PSM) that involved 42 variables covering demographics, comorbidities, medications, and laboratory results. The primary outcome of interest was MAKE, defined as stage 3 AKI, Dialysis or eGFR < 15 ml/min/1.73m2, Death at 30 days. Secondary outcomes were mortality and dialysis needing AKIs at 30 days. Adjusted hazard ratios (AHRs) with 95% CIs and P values were calculated using Cox proportional hazards regression models for all outcomes. The Kaplan-Meier method was used to estimate survival probabilities after PSM, considering 2-sided p < .05 as statistically significant. Sensitivity analyses with different observations and study window and subgroup analysis were done.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 106,141 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.